The Swedish biotech Modus Therapeutics Holding AB has entered into a partnership with a team at Imperial College London, UK to investigate the compound sevuparin in patients with severe malaria. Modus is currently developing sevuparin for sepsis and septic shock, life-threatening conditions caused by the body’s reaction to an infection. The company has now extended its research to do more work in malaria.
Verona Pharma Plc has agreed to grant exclusive rights to Nuance Pharma Ltd of Shanghai, China for its respiratory treatment ensifentrine in exchange for an upfront payment of $25 million in cash and other considerations. The rights relate to the development and commercialisation of ensifentrine in mainland China and adjacent territories. Ensifentrine is an investigational therapy, currently in a global Phase 3 programme for the treatment of chronic obstructive pulmonary disease (COPD). Late-stage clinical trials are currently underway at sites in the US, Europe and South Korea.
A new application for therapeutic RNA is being explored by the UK start-up company Transine Therapeutics Ltd. On 2 June, Transine announced receipt of an extended £9.1 million in seed financing. The funding round was co-led by Takeda Ventures Inc and the Dementia Discovery Fund (DDF), a specialist venture capital fund supported by private industry, charities, and the UK government.
The developer of a new antifungal agent designed as an inhaled therapy for invasive pulmonary aspergillosis, has received $92 million in new capital. UK-based Pulmocide Ltd will use the Series C financing to carry out a Phase 3 registration trial for the drug PC945, which is a triazole antifungal agent.
Innovative Molecules GmbH of Germany has raised €20 million from a Series A financing round to progress a treatment for herpes simplex virus, a microbe that jumped from chimpanzees to humans more than 1.6 million years ago and now infects around two-thirds of the global population. There are two forms of the virus, type 1 and type 2, which can present either as cold sores on the mouth or blisters on the genitals. Once infected, an individual has the virus for life, though in many people it remains latent.
The UK-based oncology company Iksuda Therapeutics Ltd has completed a $47 million financing round to progress a pipeline of antibody-drug conjugates (ADCs), a drug class that is seeing renewed interest from investors because of advances in conjugation technologies. The financing was co-led by the South Korean entities Mirae Asset Financial Group and Celltrion Inc.
argenx SE is to take back rights to the antibody therapeutic cusatuzumab after its partner Cilag GmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson Inc, announced plans to quit the three-year-old collaboration. Cusatuzumab is in a Phase 1b study in newly-diagnosed, elderly patients with acute myeloid leukaemia (AML). It is being tested with venetoclax and the chemotherapy azacitidine.
A new treatment for Alzheimer’s disease was approved by the US Food and Drug Administration on 7 June using a surrogate end point for clinical benefit: a reduction of amyloid beta plaque in the brain. Aduhelm (aducanumab) was given an accelerated approval. It is the first new treatment approved for Alzheimer's disease in the US since 2003.
Novo Nordisk A/S has received US Food and Drug Administration approval for its drug Wegovy (semaglutide) for the treatment of obesity – the first weight management drug to be approved by the agency since 2014. More than one-third of US adults are estimated to be obese with the highest prevalence among those in middle age. Obesity is a risk factor for multiple disorders including heart disease, stroke and diabetes.
The scientific journal Nature Communication has published data from a Phase 1/2 study of an autologous faecal microbiota transfer treatment in patients with acute myeloid leukaemia (AML). Top-line data from the study were first presented at the American Society of Hematology Annual Meeting in December 2018. With further outcome data now available, the treatment has been shown to have had a positive impact on survival after two years.